Comparative molecular docking and toxicity between carbon-capped metal oxide nanoparticles and standard drugs in cancer and bacterial infections

碳包覆金属氧化物纳米颗粒与标准药物在癌症和细菌感染中的分子对接和毒性比较

阅读:2

Abstract

INTRODUCTION: Nanoparticles (NPs) are of great interest in the design of various drugs due to their high surface-to-volume ratio, which result from their unique physicochemical properties. Because of the importance of examining the interactions between newly designed particles with different targets in the case of various diseases, techniques for examining the interactions between these particles with different targets, many of which are proteins, are now very common. METHODS: In this study, the interactions between metal oxide nanoparticles (MONPs) covered with a carbon layer (Ag(2)O(3), CdO, CuO, Fe(2)O(3), FeO, MgO, MnO, and ZnO NPs) and standard drugs related to the targets of Cancer and bacterial infections were investigated using the molecular docking technique with AutoDock 4.2.6 software tool. Finally, the PRO TOX-II online tool was used to compare the toxicity (LD(50)) and molecular weight of these MONPs to standard drugs. RESULTS: According to the data obtained from the semi flexible molecular docking process, MgO and Fe(2)O(3) NPs performed better than standard drugs in several cases. MONPs typically have a lower 50% lethal dose (LD(50)) and a higher molecular weight than standard drugs. MONPs have shown a minor difference in binding energy for different targets in three diseases, which probably can be attributed to the specific physicochemical and pharmacophoric properties of MONPs. CONCLUSION: The toxicity of MONPs is one of the major challenges in the development of drugs based on them. According to the results of these molecular docking studies, MgO and Fe(2)O(3) NPs had the highest efficiency among the investigated MONPs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。